EDIT - Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst | Benzinga
Cantor Fitzgerald has downgraded Editas Medicine Inc (NASDAQ: EDIT) to Neutral from Overweight.
The analyst says that Editas' sickle cell therapy EDIT-301 is running approximately two years behind Vertex Pharmaceuticals/CRISPR Therapeutics AG's (NASDAQ: CRSP) exa-cel and Bluebird Bio Inc's (NASDAQ: BLUE) lovo-cel.
Editas hopes to generate clinical data on reduced organ damage, which may take years to produce.
Editas's approach revolves around setting EDIT-301 apart through two key elements - Highly selective Cas12a nuclease and a unique molecular ...